CN1612746B - Hepcidin作为制备铁稳态调节剂的用途 - Google Patents

Hepcidin作为制备铁稳态调节剂的用途 Download PDF

Info

Publication number
CN1612746B
CN1612746B CN028148150A CN02814815A CN1612746B CN 1612746 B CN1612746 B CN 1612746B CN 028148150 A CN028148150 A CN 028148150A CN 02814815 A CN02814815 A CN 02814815A CN 1612746 B CN1612746 B CN 1612746B
Authority
CN
China
Prior art keywords
hepcidin
iron
mice
usf2
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN028148150A
Other languages
English (en)
Chinese (zh)
Other versions
CN1612746A (zh
Inventor
格尔·尼古拉
索菲·沃隆特
阿克塞尔·卡恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27224392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1612746(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP01401537A external-priority patent/EP1262187A1/en
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CN201010232752.2A priority Critical patent/CN101884780B/zh
Publication of CN1612746A publication Critical patent/CN1612746A/zh
Application granted granted Critical
Publication of CN1612746B publication Critical patent/CN1612746B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/90—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving iron binding capacity of blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
CN028148150A 2001-05-25 2002-05-24 Hepcidin作为制备铁稳态调节剂的用途 Expired - Fee Related CN1612746B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201010232752.2A CN101884780B (zh) 2001-05-25 2002-05-24 Hepcidin作为铁稳态调节剂的用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP01401377 2001-05-25
EP01401377.5 2001-05-25
EP01401537.4 2001-06-14
EP01401537A EP1262187A1 (en) 2001-05-25 2001-06-14 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP02290795 2002-03-29
EP02290795.0 2002-03-29
PCT/EP2002/006924 WO2002098444A2 (en) 2001-05-25 2002-05-24 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201010232752.2A Division CN101884780B (zh) 2001-05-25 2002-05-24 Hepcidin作为铁稳态调节剂的用途

Publications (2)

Publication Number Publication Date
CN1612746A CN1612746A (zh) 2005-05-04
CN1612746B true CN1612746B (zh) 2010-09-22

Family

ID=27224392

Family Applications (2)

Application Number Title Priority Date Filing Date
CN028148150A Expired - Fee Related CN1612746B (zh) 2001-05-25 2002-05-24 Hepcidin作为制备铁稳态调节剂的用途
CN201010232752.2A Expired - Fee Related CN101884780B (zh) 2001-05-25 2002-05-24 Hepcidin作为铁稳态调节剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201010232752.2A Expired - Fee Related CN101884780B (zh) 2001-05-25 2002-05-24 Hepcidin作为铁稳态调节剂的用途

Country Status (12)

Country Link
US (4) US7169758B2 (https=)
EP (2) EP1392345B2 (https=)
JP (4) JP4944360B2 (https=)
CN (2) CN1612746B (https=)
AT (1) ATE427114T1 (https=)
AU (1) AU2002321105A1 (https=)
CA (1) CA2448382C (https=)
CY (1) CY1120241T1 (https=)
DE (1) DE60231804D1 (https=)
ES (2) ES2326469T5 (https=)
TR (1) TR201806761T4 (https=)
WO (1) WO2002098444A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4944360B2 (ja) * 2001-05-25 2012-05-30 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
CA2506668C (en) 2002-11-19 2014-08-19 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
DE10349124A1 (de) 2003-10-22 2005-05-19 Roche Diagnostics Gmbh Differenzialdiagnostik mit Hepcidin
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
KR100679100B1 (ko) * 2004-10-29 2007-02-06 엘지.필립스 엘시디 주식회사 수평 전계 인가형 액정 표시 패널 및 그 제조방법
US7968091B2 (en) 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
WO2007120883A2 (en) * 2006-04-12 2007-10-25 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
MX2009000685A (es) * 2006-07-21 2009-01-30 Amgen Inc Metodo para detectar y/o cuantificar hepcidina en una muestra.
AU2007299629C1 (en) 2006-09-21 2012-05-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the HAMP gene
US20110053268A1 (en) * 2006-10-17 2011-03-03 Naohisa Tomosugi Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator
TW201307390A (zh) * 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
WO2008124768A1 (en) 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
WO2008146903A1 (ja) * 2007-05-31 2008-12-04 Naohisa Tomosugi 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法
WO2009044284A1 (en) 2007-10-02 2009-04-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies specific for human hepcidin
WO2009055078A2 (en) 2007-10-26 2009-04-30 University Of Utah Research Foundation Identification of the hepcidin binding site on ferroportin
PE20091261A1 (es) * 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
EA201170312A1 (ru) * 2008-08-06 2012-03-30 Эли Лилли Энд Компани Селективные антитела к гепцидину-25 и их применение
US20100068737A1 (en) * 2008-09-16 2010-03-18 University Of Tennessee Research Foundation Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
JP6018753B2 (ja) 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
US8999935B2 (en) * 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
DE102009034150A1 (de) 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
AR077892A1 (es) 2009-08-20 2011-09-28 Vifor Int Ag Quinolinas antagonistas de la hepcidina
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
JP2013503835A (ja) 2009-09-07 2013-02-04 ヴィフォール （インターナショナル） アクチェンゲゼルシャフト 新規なエタンジアミン系ヘプシジン拮抗薬
TW201111379A (en) 2009-09-09 2011-04-01 Vifor Int Ag Novel thiazole-and oxazole-hepcidine-antagonists
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
EP2723861A4 (en) 2011-06-21 2014-12-10 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
EP2574669B1 (en) * 2011-06-29 2018-10-17 Kabushiki Kaisha Dnaform Biological sample pretreatment method, method for detecting rna, and pretreatment kit
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
EP2976085A1 (en) 2013-03-21 2016-01-27 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US10098878B2 (en) 2014-10-10 2018-10-16 The Board Of Regents Of The University Of Texas System HIF-2α inhibitors for treating iron overload disorders
AU2017205633A1 (en) * 2016-01-08 2018-08-16 La Jolla Pharmaceutial Company Methods of administering hepcidin
WO2018165186A1 (en) * 2017-03-07 2018-09-13 Intrinsic Lifesciences Llc Assessment of chronic iron deficiency
WO2019165252A1 (en) * 2018-02-23 2019-08-29 La Jolla Pharmaceutical Company Compositions comprising hepcidin and methods of use thereof
US12011489B2 (en) 2022-03-30 2024-06-18 Christopher Key Compositions and methods for treating inflammatory disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766207B1 (fr) * 1997-07-11 2000-12-08 Rhone Poulenc Agrochimie Gene chimere codant pour la drosomycine, vecteur le contenant pour la transformation des cellules vegetales et plantes transformees obtenues resistantes aux maladies
FR2770853B1 (fr) * 1997-11-07 1999-12-31 Rhone Poulenc Agrochimie Gene codant pour la thanatine, vecteur le contenant et plantes transformees obtenues resistantes aux maladies
US7109292B2 (en) * 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3269399A (en) * 1999-03-22 2000-10-09 Universitat Zurich Transforming growth factor (tfg) beta superfamily antagonists
JP4944360B2 (ja) * 2001-05-25 2012-05-30 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
CA2506668C (en) † 2002-11-19 2014-08-19 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) † 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US7968091B2 (en) * 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
CN101522022B (zh) * 2006-09-16 2013-05-08 大豆实验室公司 利用大豆肽降低总胆固醇水平和ldl胆固醇水平的产品和方法
TW201307390A (zh) † 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
WO2009044284A1 (en) † 2007-10-02 2009-04-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies specific for human hepcidin
WO2009097461A1 (en) 2008-01-29 2009-08-06 Neoguide Systems Inc. Apparatus and methods for automatically controlling an endoscope
WO2013086143A1 (en) 2011-12-09 2013-06-13 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
CN102245626A (zh) † 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
US9315545B2 (en) 2014-04-07 2016-04-19 Merganser Biotech, Inc. Hepcidin mimetic peptides and uses thereof
KR20170043509A (ko) 2014-06-27 2017-04-21 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 및 미니-헵시딘 유사체 및 그의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Christina H et al.Hepcidin，a Urinary Antimicrobial Peptide Synthesized in theLiver.JOURNAL OF BIOLOGICAL CHEMISTRYvol.276 no.11.2001,第7806页摘要第4-8行，第7808页图2.
Christina H et al.Hepcidin,a Urinary Antimicrobial Peptide Synthesized in theLiver.JOURNAL OF BIOLOGICAL CHEMISTRYvol.276 no.11.2001,第7806页摘要第4-8行,第7808页图2. *

Also Published As

Publication number Publication date
JP2009143938A (ja) 2009-07-02
EP1392345B1 (en) 2009-04-01
TR201806761T4 (en) 2018-06-21
ES2326469T3 (es) 2009-10-13
US9234903B2 (en) 2016-01-12
JP5717319B2 (ja) 2015-05-13
CA2448382C (en) 2013-02-19
JP2012111755A (ja) 2012-06-14
EP2186524A1 (en) 2010-05-19
US20070124825A1 (en) 2007-05-31
AU2002321105A1 (en) 2002-12-16
JP2014210775A (ja) 2014-11-13
US10004784B2 (en) 2018-06-26
US9782453B2 (en) 2017-10-10
US20170340710A1 (en) 2017-11-30
JP5847231B2 (ja) 2016-01-20
WO2002098444A2 (en) 2002-12-12
ES2326469T5 (es) 2018-05-28
EP1392345B2 (en) 2018-02-28
EP1392345A2 (en) 2004-03-03
JP4944360B2 (ja) 2012-05-30
ATE427114T1 (de) 2009-04-15
US20050037971A1 (en) 2005-02-17
US20160166649A1 (en) 2016-06-16
CY1120241T1 (el) 2019-07-10
US7169758B2 (en) 2007-01-30
CN101884780A (zh) 2010-11-17
ES2693050T3 (es) 2018-12-07
CA2448382A1 (en) 2002-12-12
DE60231804D1 (de) 2009-05-14
EP2186524B1 (en) 2018-02-21
WO2002098444A3 (en) 2003-05-01
JP2004536077A (ja) 2004-12-02
CN101884780B (zh) 2018-09-21
CN1612746A (zh) 2005-05-04

Similar Documents

Publication Publication Date Title
CN1612746B (zh) Hepcidin作为制备铁稳态调节剂的用途
Gunshin et al. Cybrd1 (duodenal cytochrome b) is not necessary for dietary iron absorption in mice
Ahmad et al. Decreased liver hepcidin expression in the Hfe knockout mouse
Tolosano et al. Defective recovery and severe renal damage after acute hemolysis in hemopexin-deficient mice
Huszar et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice
Roetto et al. Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R)
Marks et al. Ala67Thr polymorphism in the Agouti‐related peptide gene is associated with inherited leanness in humans
Ferreira et al. H ferritin knockout mice: a model of hyperferritinemia in the absence of iron overload
Tolan Molecular basis of hereditary fructose intolerance: mutations and polymorphisms in the human aldolase B gene
US20050031605A1 (en) Compositions and methods of treating diabetes
EP1262187A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
US20060014178A1 (en) Use of Mrf-2 for screening and therapies
DE DK et al. DE LA RECHERCHE MEDICALE (INSERM)
US20070101445A1 (en) Transgenic mice carrying the HP-2 gene and uses as models for vascular diseases
JP2005504062A (ja) 癌治療剤としての野生型ｒａｓ
Mochel et al. Tanja Taivassalo, 6 Peter M. Andersen, 7 Andrew Singleton, 4 Tracey A. Rouault, 3 Kenneth H. Fischbeck, 2 and Ronald G. Haller5, 8, 9
Ruiz FBXL5 Is Required for the Maintenance of Cellular Andsystemic Iron Homeostasis
Makkonen HYPERTHYROIDISM AND PAPILLARY THYROID CARCINOMA IN THYROTROPIN RECEPTOR D633H MUTANT MICE
Iolascon et al. Microcytic anemia and hepatic iron overload in a child with compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100922

Termination date: 20210524

CF01 Termination of patent right due to non-payment of annual fee